Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

NCT06103682 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT06103682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06103682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
Lead sponsor
University of California, Davis
Phase
Not applicable
Overall status
Recruiting
Start date
October 5, 2023
Completion date
September 30, 2031
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, oligoprogressive, small-cell lung cancer